LACEY HARVEY: Open Payments
NPI 1861147464 · DAPHNE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,507 in 85 payments from 9 companies in 2025. Trend: 2023 $41 · 2024 $949 · 2025 $1,507
Food & beverage: $1,507
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $635 |
| Madrigal Pharmaceuticals | 7 | $248 |
| Janssen Biotech, Inc. | 15 | $239 |
| Gilead Sciences, Inc. | 10 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Phathom Pharmaceuticals, Inc. | 4 | $56 |
| Ardelyx, Inc. | 3 | $43 |
| United Therapeutics Corporation | 1 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
Products named: REZDIFFRA, TREMFYA, RINVOQ, SKYRIZI, CREON, LINZESS, ENTYVIO, VOQUEZNA.
Industry payments across AL — which companies pay providers there.
